ProteoTech, Inc.

ProteoTech, Inc.

ProteoTech, Inc.

Overview
Date Founded

1996

Headquarters

12040 115th Avenue Northeast,Kirkland, WA 98034

Type of Company

Private

Industries

Medical Support Services
Hospitals & Patient Services

Company Description

ProteoTech, Inc. operates as a private drug development company. It focuses on targeting amyloid diseases. The firm is utilizing its amyloid and proteoglycan expertise in an effort to transform the lives of victims of Alzheimer's disease, Parkinson's disease, type 2 diabetes, and systemic amyloidosis. The company was founded in 1996 and is headquartered in Seattle, WA.

Executives & Employees

Chief Executive Officer

Chief Operating & Financial Officer

Chief Medical Officer

Director of Intellectual Property

Director, Molecular Biology

Board of Directors

Chairman at ProteoTech, Inc.

Chief Executive Officer at ProteoTech, Inc.

Chief Operating & Financial Officer at ProteoTech, Inc.

Paths to ProteoTech, Inc.
Potential Connections via
Relationship Science
You
ProteoTech, Inc.
Recent Transactions
Details Hidden

ProteoTech, Inc. raised money in a private placement transaction

Details Hidden

ProteoTech, Inc. raised money in a private placement transaction

Investors
Details Hidden

Former Professor at University of Washington

Details Hidden

Cato BioVentures focuses on early-stage investment opportunities in private companies and PIPE opportunities in undervalued public companies in the life sciences sector. They target innovative therapeutics, medical devices, diagnostics and platform tools and technologies for improved drug discovery and development. Cato BioVentures seeks companies with novel therapeutics for central and peripheral nervous system disorders, cardiovascular disease, metabolic disease and cancer, with special emphasis on next generation embryonic stem cell-based technologies and skin penetration enhancement delivery systems. Cato BioVentures also seeks product development opportunities in public companies that have gone off track or fallen out of favor with the investment community. The firm's strategic services often serve as a bridge during the period between a company's formation or initial angel financing and its first institutional financing.Cato BioVentures often co-invests with other institutional investors and they generally do not require a board seat as a condition of their investment. In a board-like manner, the firm's principals regularly provide essential market, regulatory and drug development insights, as well as financial, operational and strategic advice.Cato seeks to invest in companies with a realistic business model built on reasonable assumptions, innovative drug candidates or technologies supported by a strong intellectual property position and a solid pathway to commercial protection. They prefer companies targeting a large market potential (at least $100 million in annual sales) within a reasonable amount of time (up to seven years) based upon a realistic analysis of the market from the bottom up.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by ProteoTech, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of ProteoTech, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and ProteoTech, Inc..